About VA111913 and dysmenorrhoea:
VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.
A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.
Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.
Contact details: Vantia Therapeutics Dr Jim Phillips, CEO +44(0)238-076-3433 firstname.lastname@example.org +44(0)7515-397176 Citigate Dewe Rogerson Chris Gardner / Mark Swallow / Helena Galilee +44(0)207-638-9571 email@example.com / firstname.lastname@example.org / email@example.com
|SOURCE Vantia Therapeutics|
Copyright©2009 PR Newswire.
All rights reserved